首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1736658

穿戴式注射設備市場（按類型、治療目標、最終用戶和地區）：預測至 2026-2032 年

Wearable Injectors Market By Type (On-Body Injectors, Off-Body Injectors, Hand Held), Therapy (Immuno-Oncology, Diabetes, Cardiovascular Diseases), End-User (Hospitals, Home Care Settings, Clinics), & Region for 2026-2032

出版日期: 2025年05月06日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

穿戴式注射設備市場評估（2026-2032）

穿戴式注射器小巧便攜的設計，使患者能夠在日常工作的同時輕鬆自行用藥。這種便利性，加上潛在的醫療成本節省，預計將在未來幾年大幅提升需求。因此，便利性和便攜性將推動市場規模的成長，預計到2024年市場規模將超過76億美元，到2032年將達到214.8億美元。

包括創新新藥在內的生物製藥領域的進步，正在推動對專用輸送設備的需求。因此，由於製藥業的成長，預計2026年至2032年期間市場複合年成長率將達到15.30%。

穿戴式注射設備市場定義/概述

穿戴式注射器，也稱為體內注射器或貼片幫浦，代表了醫療設備技術的顯著進步，尤其是在生物藥品和複雜治療方法的輸送方面。這些裝置旨在長時間皮下注射大量藥物，為傳統靜脈注射和每日頻繁注射提供了現代化的替代方案。穿戴式注射器佩戴在皮膚上，並可設定劑量以精確給藥，大大提高了患者的便利性和對治療方法的依從性。

穿戴式注射器主要用於治療糖尿病、類風濕性關節炎和多發性硬化症等慢性疾病，與頻繁的手動注射相比，它提供了一種創傷更小、更方便的選擇。它們可以持續或規律地給藥，減輕治療負擔，並提高患者舒適度。科技的進步將使這些設備更易於使用，並更好地融入醫療保健系統，從而有可能改善藥物輸送，增強患者照護，並最佳化醫療效果。

慢性病盛行率的上升和微流體的創新將如何推動穿戴式注射器市場的成長？

糖尿病、癌症和心血管疾病等慢性疾病的發生率不斷上升，顯著增加了對穿戴式注射器的需求。這些設備為常規藥物管理、提高治療順從性和改善患者預後提供了便捷的解決方案。例如，糖尿病患者受益於穿戴式胰島素泵，該泵永續皮下注射胰島素，與每日多次注射相比，更有效地控制血糖值。微流體、無線通訊和材料科學領域的技術進步進一步推動了穿戴式注射器的普及。微流體創新能夠精確控制藥物輸送，而無線連接則允許即時監測和數據收集，有助於更好地追蹤依從性並調整治療方案。

向家庭醫療保健的轉變也是穿戴式注射器市場的主要驅動力。患者更傾向於在家中自行治療，以避免頻繁且昂貴的醫院就診，而穿戴式注射器則透過實現自主用藥，最大限度地減少專業協助，滿足了這一需求。這一趨勢在新冠疫情期間加速發展，它還解決了針刺傷等問題，並透過減少對醫護人員參與的需求來降低醫療成本。

此外，生物感測器整合藥物輸送系統等先進設備的引入將進一步推動市場成長。這些系統利用智慧聚合物和生物微機電系統 (BioMEMS) 進行持續監測和精準藥物釋放。這些技術創新提供了快速反應的治療方案，增強了慢性疾病的管理，從而支持穿戴式注射器市場的擴張。

設備設計中的使用者體驗和生物相容性/安全性問題將如何阻礙穿戴式注射器市場的成長？

穿戴式注射器的成功很大程度上取決於其設計和使用者體驗。這些設備必須簡潔、舒適、可靠，以確保患者的遵從性和治療效果。然而，要實現滿足這些標準的設計面臨著巨大的挑戰。穿戴式注射器需要輕巧且不顯眼，以免干擾患者的日常生活，同時也要擁有直覺的使用者介面，方便患者自行給藥，尤其對於行動不便或認知障礙的患者而言。由於穿戴式注射器直接接觸皮膚將藥物輸送到體內，因此生物相容性和安全性至關重要。

穿戴式注射器的高昂成本是其廣泛應用的主要障礙。由於其技術先進且生產過程中涉及大量研發，這些設備比傳統注射方式更昂貴。高昂的製造成本也使患者和醫療保健系統難以承受，尤其是在成本至關重要的中低收入國家。口服胰島素等替代給藥方式的出現也對穿戴式注射器市場構成了挑戰。

Wearable injectors' compact, portable design allows patients to self-administer medications easily while continuing daily activities. This convenience, combined with potential healthcare cost savings, is expected to boost demand significantly in the coming years. Thus, convenience and portability surge the growth of market size surpassing USD 7.6 Billion in 2024 to reach a valuation of USD 21.48 Billion by 2032.

Advancements in biopharmaceuticals, which involve new and innovative drugs, are increasing the need for specialized delivery devices. Thus, the growth in the pharmaceutical industry enables the market to grow at a CAGR of 15.30% from 2026 to 2032.

Wearable Injectors Market: Definition/ Overview

Wearable injectors, also known as on-body injectors or patch pumps, represent a notable advancement in medical device technology, particularly for delivering biological medications and complex therapies. These devices are engineered to administer larger doses of medication subcutaneously over extended periods, providing a modern alternative to traditional intravenous infusions and frequent daily injections. By being worn on the skin and programmed to deliver precise medication doses, wearable injectors significantly enhance patient convenience and adherence to treatment regimens.

Primarily used for managing chronic conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis, wearable injectors offer a less invasive and more convenient option compared to frequent manual injections. They allow for continuous or scheduled medication delivery, easing the burden of treatment and improving patient comfort. The advancements in technology are set to make these devices even more user-friendly and integrated into healthcare systems, promising improved drug delivery, enhanced patient care, and optimized healthcare outcomes.

How do the Rising Prevalence of Chronic Diseases and Innovations in Microfluidics Surge the Growth of the Wearable Injectors Market?

The rising prevalence of chronic conditions such as diabetes, cancer, and cardiovascular diseases has significantly increased the demand for wearable injectors. These devices offer a convenient solution for managing regular medication, enhancing treatment compliance, and improving patient outcomes. For instance, diabetic patients benefit from wearable insulin pumps that deliver continuous subcutaneous insulin, effectively managing blood glucose levels compared to multiple daily injections. Technological advancements in microfluidics, wireless communication, and materials science have further boosted the popularity of wearable injectors. Microfluidic innovations enable precise control over drug delivery rates, while wireless connectivity allows real-time monitoring and data collection, facilitating better adherence tracking and treatment adjustments.

The shift toward home-based healthcare is another major driver for the wearable injectors market. Patients prefer home treatments to avoid frequent, costly hospital visits, and wearable injectors accommodate this need by allowing the self-administration of medications with minimal professional assistance. This trend, which accelerated during the COVID-19 pandemic, also addresses issues like needle stick injuries and reduces healthcare costs by decreasing the need for healthcare worker involvement.

Additionally, the introduction of advanced devices like biosensor-integrated drug delivery systems, which use smart polymers and bioMEMS for continuous monitoring and precise drug release, further propels market growth. These innovations provide rapid, responsive treatment options, enhancing the management of chronic diseases and supporting the expansion of the wearable injectors market.

How do the Device Design User Experience and Biocompatibility and Safety Concerns Impede the Growth of the Wearable Injectors Market?

The success of wearable injectors largely depends on their design and user experience. These devices must be simple, comfortable, and reliable to ensure patient adherence and treatment effectiveness. However, achieving a design that meets these criteria poses significant challenges. Wearable injectors need to be lightweight and discreet to avoid disrupting patients' daily activities, while also featuring an intuitive user interface for easy self-administration, especially for patients with limited dexterity or cognitive impairments. Wearable injectors come into direct contact with the skin and deliver medication into the body, making biocompatibility and safety-critical.

The high cost of wearable injectors is a major barrier to their widespread adoption. These devices are more expensive than traditional injection methods due to their sophisticated technology and the extensive research and development involved in their creation. The high manufacturing costs can make them unaffordable for patients and healthcare systems, particularly in low- and middle-income countries, where cost considerations are paramount. The availability of alternative drug delivery methods, such as oral insulin, presents another challenge for the wearable injectors market.

Category-Wise Acumens

How does the Increasing Demand for Patient-Centric Treatment and the Growing Prevalence of Cancer Surge the Growth of the Immuno-Oncology Segment?

The immuno-oncology segment has emerged as the dominant force in the wearable injectors market due to the rising prevalence of various cancers, including breast, lung, bowel, and uterine cancers. This surge in cancer diagnoses has spurred demand for advanced, patient-centric treatment options. Immuno-oncology treatments, which use the body's immune system to combat cancer, often involve administering complex biological drugs like monoclonal antibodies and immune checkpoint inhibitors. These therapies require precise, continuous administration over extended periods, making wearable injectors a crucial tool.

The growing trend toward patient self-administration is further fueling the demand for wearable injectors. Traditional cancer treatments frequently require frequent healthcare visits for infusions, which can be costly and uncomfortable. Wearable injectors allow patients to administer their medications at home, enhancing convenience, improving quality of life, and reducing healthcare costs and facility strain. As the incidence of cancer increases, the need for scalable and accessible treatment solutions becomes more pressing. Wearable injectors address these needs by simplifying drug delivery and improving adherence to treatment plans, solidifying their importance in the immuno-oncology market and ensuring their continued growth.

How does the Increasing Demand for Devices and Automated Warming Surge the Growth of the On-Body Injectors Segment?

The on-body injectors segment has emerged as the largest revenue contributor in the wearable injectors market, driven by their numerous advantages and growing demand. Designed as patches worn comfortably on the skin, typically around the stomach area, on-body injectors have become highly preferred due to their user-friendly design, water-resistant properties, and suitability for home-based care. These devices are particularly valued for their convenience, as they deliver complex medications over extended periods, making them essential for managing chronic conditions. By allowing patients to self-administer medications at home, on-body injectors reduce the frequency of hospital visits, significantly lowering healthcare costs and alleviating the burden on medical facilities.

On-body injectors prioritize ease of use and patient comfort. Their lightweight, discreet design does not interfere with daily activities, leading to widespread adoption among various patient populations. The skin-friendly nature of these devices allows for extended wear without discomfort or irritation, further enhancing their appeal. The shift toward home-based care, accelerated by the COVID-19 pandemic, has driven the demand for on-body injectors, as patients increasingly prefer to receive treatments at home rather than frequent healthcare facilities.

How the Increasing Prevalence of Chronic Diseases and Advanced Healthcare Infrastructure Surge the Growth of Wearable Injectors Market in North America?

North America stands as the dominant region in the wearable injectors market, a position it is expected to maintain throughout the forecast period owing to its advanced healthcare infrastructure, high prevalence of chronic diseases, and early adoption of innovative technologies. The region's commitment to patient-centered care, alongside efforts to reduce healthcare costs and enhance treatment convenience, reinforces its leadership in this market. The rising incidence of chronic conditions, such as cancer and diabetes, has created a significant demand for efficient and reliable drug delivery systems. For instance, wearable insulin pumps have become crucial for managing diabetes by providing continuous subcutaneous insulin infusion and reducing the need for multiple daily injections.

The region has consistently led in medical device innovation, supported by substantial investments in research and development (R&D). This has facilitated the rapid advancement and adoption of sophisticated wearable injectors, which feature technologies like wireless connectivity, microfluidics, and patient monitoring systems. These innovations ensure more precise, efficient, and user-friendly drug delivery, which enhances patient outcomes and adherence to treatment regimens. Leading players in the region are actively engaged in product launches, mergers, acquisitions, and collaborations to expand their portfolios and market reach.

How does the Adoption of Wearable Medical Devices and Advanced Wearable Injectors Foster the Growth of the Wearable Injectors Market in Asia Pacific?

The Asia Pacific region is poised for the fastest growth in the wearable injectors market, driven by the widespread adoption of advanced medical technologies. Governments across the region, including those in China, India, and South Korea, are actively supporting this trend with favorable policies, subsidies, and streamlined regulatory processes that promote the use of wearable injectors. These initiatives aim to enhance healthcare infrastructure, address the needs of an aging population, and manage the rising incidence of chronic diseases.

The growing senior population, which faces higher risks of conditions such as diabetes, cardiovascular diseases, and cancer, further fuels the demand for wearable injectors. These devices offer a practical solution for self-administration, reducing the need for frequent hospital visits and improving patient management. As the geriatric demographic expands, the demand for wearable injectors is expected to accelerate significantly.

Competitive Landscape

The Wearable Injectors Market is a dynamic and competitive landscape. Key players are focused on innovation, partnerships, and market expansion to meet the growing demand for these devices. As the market continues to evolve, we can expect to see further advancements in wearable injector technology and increased adoption in various therapeutic areas.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the wearable injectors market include:

Valeritas
SteadyMed Therapeutics
Tandem Diabetes Care
Amgen
Medtronic
Insulet Corporation
United Therapeutic Corporation
Enable Injections
Ypsomed
Becton
Dickinson and Company

Latest Developments:

In February 2023, Insulet Corporation, a medical device business, announced the acquisition of Automated Glucose Control LLC's (AGC) assets. AGC was a key industry player in developing and commercializing automated insulin administration technologies.
In May 2023, Enable Injections announced the collaboration with Viridian Therapeutics, Inc. to improve the patient experience using enFuse, a revolutionary wearable drug delivery device.
In November 2022, Medtronic Plc announced the launch of the Medtronic Extended infusion set, a first-of-its-kind product that may be worn for up to 7 days in the United States. This infusion set is suitable for the MiniMed 600 and 700 series.
In April 2021, Medtronic announced the launch of a wearable injector for diabetes therapy, which patients can wear for 7 days.

1 INTRODUCTION OF GLOBAL WEARABLE INJECTORS MARKET

1.1 Introduction of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL WEARABLE INJECTORS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL WEARABLE INJECTORS MARKET, BY TYPE

5.1 Overview
5.2 On-Body Injectors
5.3 Off-Body Injectors

6 GLOBAL WEARABLE INJECTORS MARKET, BY THERAPY

6.1 Overview
6.2 Immuno-Oncology
6.3 Diabetes
6.4 Cardiovascular Diseases

7 GLOBAL WEARABLE INJECTORS MARKET, BY END-USER

7.1 Overview
7.2 Hospitals
7.3 Clinics
7.4 Home Care Settings

8 GLOBAL WEARABLE INJECTORS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL WEARABLE INJECTORS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Valeritas
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 SteadyMed Therapeutics
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Tandem Diabetes Care
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Amgen
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Medtronic
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Insulet Corporation
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 United Therapeutic Corporation
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Enable Injections
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Ypsomed
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Becton, Dickinson, and Company
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments